Drugs / A9-DPC
A9-DPC
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05887466 | May 2023 → Dec 2025 | Parkinson disease | S.Biomedics Co., Ltd. | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06477744 | Sep 2023 → Feb 2029 expected | Parkinson disease | S.Biomedics Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | A9-DPC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06477744 ↗ |
| Known as | Allogenic embryonic stem cell-derived A9 dopamine progenitor cell | “IP Name : Allogenic embryonic stem cell-derived A9 dopamine progenitor cell (A9-DPC)” NCT06477744 ↗ |
| Modality | Cell therapy | “allogenic embryonic stem cell-derived A9 dopamine progenitor cell (A9-DPC) therapy” NCT05887466 ↗ |
| Route | Other | “the cells are injected at a predetermined stem cell administration point of the putamen in the brain of the subject.” NCT05887466 ↗ |